Recreational ketamine use has increased in the United States in recent years, outpacing its rise as a treatment for depression, a new analysis suggests. The hallucinogenic drug — a controlled ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Misuse and addiction. Even deaths ... says doctors began to realize that the drug had powerful effects against depression and suicidal thoughts. “Someone is trying to jump off a bridge and ...

A new review from the Cochrane Database of Systematic Reviews confirms that antidepressants can effectively reduce symptoms ...

Ketamine is a short-acting anesthetic that has been used for decades in medical settings. In recent years, researchers have ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for Spravato (esketamine) as a monotherapy for adults living with ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and hay fever.

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being developed in Hamilton after a McMaster University researcher discovered a new ...